Understand the source comparison
PE-22-28 Alternatives 2026 Best: Research Application Comparison
| Peptide | Primary Mechanism | Optimal Administration | Effective Dose Range (Rodent Models) | BBB Penetration Method | Unique Research Application | Professional Assessment ||—|—|—|—|—|—|| Dihexa | HGF/c-Met receptor potentiation; BDNF-independent synaptogen
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Peptide | Primary Mechanism | Optimal Administration | Effective Dose Range (Rodent Models) | BBB Penetration Method | Unique Research Application | Professional Assessment ||—|—|—|—|—|—|| Dihexa | HGF/c-Met receptor potentiation; BDNF-independent synaptogenesis | Oral or subcutaneous | 0.5–2.0 mg/kg oral daily | Passive lipophilic diffusion | Chronic neurodegenerative models where long-term oral dosing is required | Highest in vitro potency; best oral bioavailability; limited safety data in primates || P21 | ADNF-derived STAT3 activation; astrocyte-mediated neuroprotection | Intranasal preferred | 1.0 mg/kg intranasal 3×/week | Direct olfactory/trigeminal nerve transport | Acute CNS injury models (TBI, stroke) with compromised BBB | Superior BBB penetration via intranasal route; well-tolerated across species; mechanism distinct from TrkB pathways || Cerebrolysin | Multi-modal neurotrophic factor mixture (BDNF-like, NGF-like, CNTF-like) | Intravenous infusion | 2.5–5.0 mL/kg IV daily